Nalbuphine versus tramadol for post-operative pain after abdominal surgery in children with cancer
Comparative Study Between Nalbuphine Versus Tramadol on Post Operative Analgesia in Abdominal Surgery on Pediatric Cancer Patient
This trial tests whether nalbuphine or tramadol better controls pain after abdominal surgery in children aged 3–12 with cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 128 (estimated) |
| Ages | 3 Years to 12 Years |
| Sex | All |
| Sponsor | National Cancer Institute, Egypt Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT07110051 on ClinicalTrials.gov |
What this trial studies
Children with cancer aged 3–12 who are scheduled for elective abdominal surgery under general anesthesia will receive either nalbuphine or tramadol for postoperative pain management. Investigators will monitor pain scores and common opioid-related side effects such as respiratory depression, nausea/vomiting, and pruritus in the immediate postoperative period. Patients with allergies to the study drugs or on chronic opioid therapy are excluded. The goal is a direct comparison of analgesic effectiveness and safety between the two drugs in this surgical pediatric population.
Who should consider this trial
Good fit: Children aged 3–12 years with cancer, ASA class I–III, scheduled for elective abdominal surgery under general anesthesia, who are not allergic to nalbuphine or tramadol and are not on chronic opioids.
Not a fit: Children outside the 3–12 age range, those allergic to either drug, those already using chronic opioids, or those having emergency procedures are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this could identify which opioid provides better pain relief with fewer side effects for children with cancer after abdominal surgery.
How similar studies have performed: Prior adult studies and some pediatric reports show tramadol provides effective analgesia with comparatively fewer adverse effects, but direct head‑to‑head pediatric comparisons with nalbuphine after abdominal surgery are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants will be children aged 3-12 years * American society of anesthesia (ASA) classification I-III. * scheduled for elective Abdominal surgery under general anesthesia Exclusion Criteria: * child guardian refusal. * Allergy from Tramal or nalbuphine * Patient with previous chronic pain on opioids
Where this trial is running
Cairo
- National cancer institute — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Reham mohamed gamal, MD — assistant professor
- Study coordinator: Norma Osama AbdAllah Zayed, MD
- Email: norma.osama@nci.cu.edu.eg
- Phone: 01067843111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.